Rayno Life Science Portfolios With Sector Up 20% YTD 6/20/13

cheap date lyrics Rayno Diagnostics and Tools Portfolio    Prices as of 5/29/13

  • Top 2013 Winners: buy Lyrica with mastercard ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML
  • Sector high was in mid-May
  • Less volatile than biopharma but more dependent on earnings
  • Five companies on focus list were acquired over 3 years
2010-2013 Original Price Price % Price Price % RET buy provigil in india Price %RET
DX and Tools Recomm Dec’10 Ret 10/2/12 1/2/13 1 yr 5/29/13 YTD
Abaxis ABAX 2/2/09 15 26.9 79 37.9 37.8 36.7 44.7 18.2
BG Medicine BGMD 5/15/13 1.73 NEW 2.32 -58 1.83 5.8
CardioV.Sys. CSII 11/5/10 7.15 11.7 63 11.45 13 29.7 19.88 53
Celera CRA 3/28/10 7 6.3 18 acquired
Cepheid CPHD 10/23/12 31.4 NEW 35.5 13 37.33 5
Exact Sci EXAS 12/10/10 5.6 5.98 6.8 11.36 11 36 11.12 1
GenomicH GHDX 2/26/13 28.5 NEW 27.24 6.3 37 35.6
GenProbe GPRO 2/2/09 45 58.4 30 82.55 acquired
Hologic HOLX 4/9/13 21.6 NEW 20 20.17 -6.5
Illumina ILMN 2/2/09 29 63.3 118 51.2 55.4 81.8 71 27
Immucor BLUD 4/5/10 20 19.8 0 acquired
Alere ALR 2/2/09 25 36.6 46 19.64 19 -18 25.37 33.5
MicroFluidics MFLU 7/6/10 0.77 1.34 74 acquired
NeoGen NEOG 7/2/10 26 41 58 42.8 45.6 48.8 55.15 21
Qiagen QGEN 3/15/10 21.5 19.6 -9 19 18.8 36 18.91 0
Quidel QDEL 6/16/10 12.4 14.5 16 18.65 19.9 31.3 23.15 16.3
ResponseG RGDX 2/3/12 1.5 1.3 1.4 -13 1.49 6
Sequenom SQNM 11/18/09 3.75 8.03 114 3.5 4.93 10.8 4.04 -23
SeraCare SRLS 11/18/09 2.75 4.75 73 acquired
ThermoFish TMO 7/25/12 53.5 NEW 59.4 65 44.5 87.36 34
Vermillion VRML 5/15/13 2.53 NEW 1.37 73 3.71 47

 

Rayno Biopharmaceuticals Portfolio After 6.5% IBB Correction Since May 21 

  • Top 2013 Winners: AMRI, ASTX, BIIB, GILD, PCYC, SGEN   All Over 30% YTD
  • Sector High was in mid may May  IBB 187
  • Two 2013 Losers: ACHN (new), ALXN off 8%
  • Volatility due to hedge fund investing and momentum trades
2013 Price Original P Price %Ret Price Price % Ret Price
Summary Jy’10 Recomm Dec’10 2010 Apr’11 Dec’12 YTD’13 20-Jun
Achillion ACHN 3/4/13 8.6 -8.1 7.9
Alexion ALXN 50.45 2/2/09 35 80.6 130 100.8 95.4 -8 88.47(sp)
Alkermes ALKS  added 3/22/13 23 18.5 17 27
Albany Mol AMRI 2/10/11 4.68 added 4.32 5.3 116 11.46
Astex ASTX 12/27/11 1.63 2.7 67 4.5
Amgen AMGN 51.7 2/2/09 55 54.9 0 54 87.4 10 96.28
Biogen BIIB 49.42 2/2/09 48.5 67.1 37 73.25 149 33 199.58
Cephalon CEPH 55.95 2/2/09 76.5 61.7 -19 76.92 80.18 30 acquired
Cubist CBST 20.7 2/2/09 21.5 21.4 -3 28.35 42.4 15 49
Exelixis EXEL trade 9/2/10 3.3 8.21 148 11.12 4.58 0 4.56
First Trust FBT 30.4 4/15/10 37.5 39.1 3 41.3 46 19.5 55.1
Gilead GILD 34.9 2/2/09 51 36.2 -29 42.81 72.7 34 49.38(sp)
iShares ETF IBB 76.6 2/2/09 70.5 93.4 32 101.1 137.8 22 167.92
SPDR Bio XBI 86.38 17.4 101.29
Micromet MITI 6.28 2/2/09 4 8.12 103 5.46 10.91 272 acquired
ImmunoGen IMGN 12/22/11 12.4 12.5 23 15.37
Optimer OPTR trade 2/18/11 11.8 added 13.8 9.2 51.6 13.72
Pharmacycl PCYC 6/8/12 38.2 58 40 81.29
Regeneron REGN 21.6 2/2/09 17.5 32.8 82 45.43 173 28.3 219.61
Seattle Gen. SGEN 11.85 2/2/09 9.5 15 57 15.72 23.3 33 31.01
ViroPharma VPHM 10.88 2/2/09 12 17.3 44 20.05 22.9 22 27.9
Paired Trades
Pharmacycl PCYC long 6/8/12 38.2 60 51 81.29
Medivation MDVN short 6/8/12 86.8 closed 50 7 45.21(split)
net 58
Alkermes ALKS long 3/22/13 23 18.5 27 27
Infinity INFI short 3/22/13 48.7 closed 35 18 18.36
net 45

, , , , , , ,

No comments yet.

Leave a Reply